Essay On Botulism

946 Words2 Pages

Inhibitors against BoNT/A The detailed mechanism of BoNT pathogenicity and the structure-function relationship of BoNT provide invaluable targets for development of the antidotes and inhibitors against botulism. The BoNT molecule is divided in clear functional domains that can operate independently. This feature provides multiple targets for designing therapeutics to treat botulism. High throughput screening and the combinatorial chemistry provide another useful tool for screening the inhibitors against botulism (Cai and Singh, 2007). Early work with zinc metalloprotease inhibitors focused on the well-characterized agents captopril ((2S)-1-[(2S)-2-methyl-3-sulfanyl-propanoyl] pyrrolidine-2-carboxylic acid) and phosphoramidon (N-alpha-L-rhamno pyranosyl oxy [hydroxyl phosphinyl]-L-leucyl-L-tryptophan). These compounds, however, were found to have little inhibitory activity against BoNT (Adler et al., 1994, 1999a). Phosphoramidon analogs in which Leu–Trp was replaced by Phe–Glu to resemble the cleavage site of synaptobrevin exhibited little increase in inhibitory activity (Adler et al., 1999a). So far, numerous peptide and small molecule based inhibitors have been identified by several researchers. Schmidt et al., (1998) made single residue changes near the cleavage site of a 17-mer SNAP-25 peptide that was a minimal substrate for BoNT/A. The best inhibitors in this series had Ki values of ~2 mM in cell-free assays. With further elaboration of this approach, more potent inhibitors were developed, as exemplified by the pseudo peptide, 2-mercapto-3-phenylpropionyl-RATKML (Ki=0.33 mM; Schmidt and Stafford, 2002). Burnett et al. (2007) examined the interaction of this molecule with the active site of BoNT/A LC. Sukonpan et al. (2004) a... ... middle of paper ... ...ubstrate by non-perfectly conserved residues’ and by ‘the residues flanking the active-site region.’ This suggestion is consistent with the observation that two exosites are crucial for SNAP-25 binding to the LC of BoNT/A (Breidenbach and Brunger, 2004). The α- and ß-exosites were recognized as being potentially important in the development of specific inhibitory drugs, and targeting the peripheral sites of substrate binding has focused on a family of bis-imidazole inhibitors for BoNT/A (Merino et al., 2006). A recent study by Eubanks et al. (2007) has highlighted limitations of conventional drug development paradigms. The authors found that high-throughput screens did not consistently predict the candidates that would be most effective in their cell-based assays. Eubanks et al. (2007) also observed that efficacy in cell culture did not predict protection in vivo.

More about Essay On Botulism

Open Document